NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

FINANCIAL STATEMENTS

31 MARCH 2022

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2022

Contents

Page

Statement of Directors' responsibilities in relation to the financial statements

1

Statement of Compliance

2

Independent Auditor's Report

3

Statement of financial position

7

Statement of profit or loss and other comprehensive income

8

Statement of changes in equity

9

Statement of cash flows

10

Notes to the financial statements

11

Other national disclosures:

Statement of value added

48

Financial summary

49

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MARCH 2022

31-Mar-22

31-Mar-21

Note

N'000

N'000

Turnover

8

985,247

1,281,576

Cost of sales

9

(559,534)

(741,208)

Gross profit / (Loss)

425,713

540,368

Other income

10

12,448

11,199

Marketing and distribution expenses

11

(296,596)

(272,117)

Administrative expenses

12

(318,876)

(226,330)

Exchange Gain

13

3,455

17,506

Operating profit

(173,856)

70,626

Finance costs

14

(35,077)

(42,316)

Loss before taxation

(208,933)

28,310

Income tax expense

28

-

-

Loss for the year from continued operation

(208,933)

28,310

Other comprehensive income

Gain on available for sale assets

-

-

Total other comprehensive income

-

-

Total comprehensive Loss

(208,933)

28,310

Basic (loss)/earnings per share

32

(11)

1.49

The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.

8

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MARCH 2022

31-Mar-22

Oct'21 - Mar'22

Oct'20 - Mar'21

Note

N'000

N'000

N'000

N'000

Turnover

8

793,134

985,247

887,014

1,281,576

Cost of sales

9

(381,304)

(559,534)

(444,633)

(741,208)

Gross profit / (Loss)

411,830

425,713

442,381

540,368

Other income

10

6,467

12,448

6,110

11,199

Marketing and distribution expenses

11

(138,308)

(296,596)

(144,229)

(272,117)

Administrative expenses

12

(169,913)

(318,876)

(109,933)

(226,330)

Exchange Gain

13

11,909

3,455

19,423

17,506

Operating profit

121,985

(173,856)

213,752

70,626

Finance costs

14

(21,805)

(35,077)

(6,654)

(42,316)

Loss before taxation

100,180

(208,933)

207,098

28,310

Income tax expense

28

-

-

-

-

Loss for the year from continued operation

100,180

(208,933)

207,098

28,310

Other comprehensive income

Gain on available for sale assets

-

-

-

-

Total other comprehensive income

-

-

-

-

Total comprehensive Loss

100,180

(208,933)

207,098

28,310

Basic (loss)/earnings per share

32

5.27

(11.00)

10.90

1.49

31-Mar-21

The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.

8

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Neimeth International Pharmaceuticals plc published this content on 29 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 April 2022 16:47:12 UTC.